This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Correction

 

Published: October 24, 2018

Correction:

In the article "Reduction of Alcohol Drinking in Young Adults by Naltrexone: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety" by Stephanie S. O’ Malley, PhD, and colleagues published in the February 2015 issue (J Clin Psychiatry 2015;76[2]:e207-e213), in Figure 1, the numbers of participants who discontinued intervention have been corrected as follows. In the naltrexone condition, the total n = 9 (not interested, n = 6; family emergency, n = 1; medical contraindication, n = 1; adverse event/not interested, n = 1). In the placebo condition, the total n = 7 (not interested, n = 6; medical contraindication, n = 1).

Volume: 79

Quick Links: Addiction , Substance Use Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...